Keryx Biopharmaceuticals — Q2 2017 Earnings Presentation
16 slides from Keryx Biopharmaceuticals's earnings presentation, Jul 27, 2017
Slide 1: Second Quarter 2017 Financial Results
Keryx Biopharmaceuticals, Inc. Second Quarter 2017 Financial Results July 27, 2017 Building a Leading Renal Company Exhibit 99.2
Slide 2: Agenda – Second Quarter 2017 Financial Results
Agenda – Second Quarter 2017 Financial Results Topic Speakers Introduction Amy Sullivan, SVP, Corporate Affairs Business Highlights Greg Madison, President & CEO 2017 Guidance/2Q’17 Results Scott Holmes, SVP & CFO Maximizing Auryxia® Doug Jermasek, VP, Marketing & Strategy Question & Answer All
Slide 3: Forward-looking Statements
Forward-looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development of Auryxia, our updated 2017 financial guidance and the submission of an sNDA to the FDA to expand the label of ferric citrate to inclu
Slide 4: Recent Business Progress
Recent Business Progress Greg Madison President and Chief Executive Officer
Slide 5: Recent Business Progress
Reported ~21,100 prescriptions for 2Q’17, a 61% increase compared to 2Q’16 Increased 2017 net U.S. Auryxia product sales guidance to $62 to $66 million from $56 to $60 million Recent formulary additions at two major Part D providers, which increased access to 95% across Medicare Part D and commercia
Slide 6: Financial Highlights
Financial Highlights Scott Holmes SVP and Chief Financial Officer
Slide 7: Guidance: 2017 Net U.S. Auryxia Product Sales
Guidance: 2017 Net U.S. Auryxia Product Sales Increased 2017 Auryxia guidance to $62 to $66 million, from $56 to $60 million, based upon: Strong 2Q prescription level and underlying demand Impact of broad formulary access: 95% of phosphate binder patients with Medicare Part D and commercial insuranc
Slide 8: Strong 2Q 2017 Auryxia Prescription Demand
Sources: IMS, Davita Rx, Fresenius Rx and Keryx data on file. Strong 2Q 2017 Auryxia Prescription Demand +61% IMS / Specialty mix 2Q 2017: 54% / 46% prescriptions
Slide 9: Selected Second Quarter 2017 Financial Results
Selected Second Quarter 2017 Financial Results ($ in millions) 2Q 2017 (unaudited) 2Q 2016 (unaudited) Net U.S. Auryxia Product Sales $ 14.1 $ 8.3 License Revenue $ 1.0 $ 1.0 Total Revenue $ 15.1 $ 9.3 Cost of Goods Sold $ 4.4 $ 5.1 Operating Expenses* $ 34.0 $ 27.2 Net loss** $ 86.5 $ 44.7 (In mill
Slide 10: Maximizing Auryxia
Maximizing Auryxia® Doug Jermasek Vice President, Marketing and Strategy
Slide 11: Strong Performance Driven by Multiple Factors
Increased breadth and depth of prescribing High level of brand awareness and growing clinical familiarity Increased yield from our prescriber interactions and growth in number of new Auryxia patients Positive clinical experience with Auryxia Early signs of recent Medicare Part D formulary additions
Slide 12: Near-term Focus to Maximize Potential of Auryxia
Near-term Focus to Maximize Potential of Auryxia Significantly more dialysis patients could benefit from treatment with Auryxia Foundation PDUFA for second indication 11/6/17 Strong momentum in dialysis provides solid foundation for IDA opportunity Meaningful progress with pre-launch preparations La
Slide 13: Maximizing the Potential for Auryxia: IDA Opportunity
Maximizing the Potential for Auryxia: IDA Opportunity Provides Significant Leverage 95 Renal Sales Specialists Current Physician Targets Care for 450,000 dialysis patients Care for 1.7 million pre-dialysis CKD patients Auryxia Conversations Auryxia Covered on all major Medicare Part D and Commercial
Slide 14: Closing Remarks
Closing Remarks Greg Madison President and Chief Executive Officer
Slide 15: Key Takeaways
Key Takeaways Strong second quarter 2017 growth supports $62 to $66 million in full year 2017 net U.S. Auryxia product sales guidance Large unmet need in iron deficiency anemia; preparing for potential launch of Auryxia for second indication, pending approval in November 2017 Second indication would
Slide 16: Second Quarter 2017 Financial Results
Keryx Biopharmaceuticals, Inc. Second Quarter 2017 Financial Results July 27, 2017 Building a Leading Renal Company
Keryx Biopharmaceuticals — Q2 2017 Earnings Presentation on 6ix